Corporate$ACAD7:01 AM ETdeveloping · v1

Acadia Pharmaceuticals reports Phase 2 topline results for remlifanserin in Alzheimer's disease psychosis; narrowly misses primary endpoint but shows efficacy trends supporting Pha

By BORSA NewsroomPublished Sep 24, 2026, 7:01 AM EDTUpdated Sep 24, 2026, 11:20 AM EDT

Acadia Pharmaceuticals Phase 2 remlifanserin narrowly misses primary endpoint, supports Phase 3 continuation

Sentimentbullish 70

Bullish · 70 of 100

Impact70

medium · sector-wide

Confidence95%

high confidence · 3 wires

Eventdeveloping

v1 · alerts feed only

WHAT WE KNOW

Phase 2 RADIANT study evaluated remlifanserin 60 mg and 30 mg once daily vs placebo in Alzheimer's disease psychosis (ADP).